Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of false and misleading statements regarding the launch of its Inspire V device, which has led to significant financial losses for investors [2][4]. Company Overview - Inspire Medical Systems, Inc. is a publicly traded company on the NYSE under the ticker INSP [2]. - The company has faced serious challenges in launching its new Inspire V device, including logistical issues and weak market demand [5][6]. Legal Proceedings - A federal securities class action has been filed against Inspire Medical, with a deadline of January 5, 2026, for investors to seek the role of lead plaintiff [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [7]. Financial Impact - On August 4, 2025, Inspire Medical announced significant setbacks in the launch of the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [5][6]. - Following the announcement, Inspire's stock price plummeted over 32%, from $129.95 per share to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [6]. Issues with Product Launch - The company reported that the rollout of the Inspire V device was delayed due to treatment centers not completing necessary training and onboarding [5]. - Billing and reimbursement challenges were also highlighted, as Medicare's approval of a CPT code for Inspire V did not coincide with the necessary software updates for claims processing [5]. Call for Information - Faruqi & Faruqi encourages anyone with information regarding Inspire Medical's conduct, including whistleblowers and former employees, to come forward [8].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock, with the case pending in the U.S. District Court for the District of Minnesota [3]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V was facing an "elongated timeframe," leading to a reduction in 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8]. Reasons for Stock Drop - The delays in the rollout of Inspire V were attributed to inadequate preparation for clinicians and payors, resulting in significant adoption delays and weak demand due to customers having excess inventory of older devices [6][7].

Core Viewpoint - A class action securities lawsuit has been filed against Inspire Medical Systems, Inc. due to alleged securities fraud affecting investors between August 6, 2024, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that the launch of Inspire Medical's new product, Inspire V, was unsuccessful due to poor demand and excess inventory at treatment centers, contradicting the company's assurances of a successful launch [2] - Allegations include the company's failure to complete essential tasks for the product launch, such as training for treatment center customers, setting up IT systems, and ensuring proper Medicare reimbursement [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors regarding operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [2][3]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, causing a bottleneck in revenue generation [3]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [3]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [3]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the January 5, 2026, Lead Plaintiff Deadline to discuss their legal rights [2][4]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [4].

Core Insights - Inspire Medical Systems faced significant setbacks in the launch of its new Inspire V device, revealing that the rollout was delayed due to incomplete training and onboarding at treatment centers [3] - The company also encountered billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, affecting the ability of implanting centers to bill for procedures [3][4] - Inspire reported weak demand and excess inventory for the Inspire V, leading to a drastic cut in its 2025 earnings guidance by over 80% [4] Financial Impact - Following the announcement of these issues, Inspire's stock price plummeted by more than 32%, dropping from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [4] Legal Proceedings - A class action lawsuit has been initiated against Inspire Medical Systems, alleging that the company and its executives made false and misleading statements regarding the market demand for Inspire V and the steps taken for its launch [2][5] - The lead plaintiff in the lawsuit is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026 [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by January 5, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and readiness for launch, leading to misleading statements that caused investor losses when the truth was revealed [5].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][5]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, causing a bottleneck in revenue generation [4]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed the necessary training and onboarding for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the Lead Plaintiff Deadline of January 5, 2026 [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that management prioritized a narrative of seamless transition over actual operational realities [5]. - Whistleblowers with non-public information regarding Inspire are encouraged to assist in the investigation, with potential rewards of up to 30% of any successful recovery made by the SEC [6].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Inspire Medical Systems, Inc. related to the company's Inspire V product launch [1]. Group 1: Company Performance Issues - The Inspire V launch is reportedly struggling due to low demand, attributed to providers holding excess inventory and disincentives from reduced physician payments [2]. - Critical issues have arisen during the launch, as Inspire failed to complete necessary tasks to support it, including training and onboarding for treatment centers [2]. - The company did not secure required IT approvals for the installation of the SleepSync program at treatment centers, nor did it ensure that claims processing systems and reimbursement codes were ready at launch [2]. - Positive statements made by the company regarding its preparedness and progress for the Inspire V launch have been deemed materially false or misleading [2].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].